Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial-Reference-Cited by-同舟云学术

Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

Published:2017-05 Issue:5 Volume:18 Page:631-639
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Kudo Toshihiro,Hamamoto Yasuo,Kato Ken,Ura Takashi,Kojima Takashi,Tsushima Takahiro,Hironaka Shuichi,Hara Hiroki,Satoh Taroh,Iwasa Satoru,Muro Kei,Yasui Hirofumi,Minashi Keiko,Yamaguchi Kensei,Ohtsu Atsushi,Doki Yuichiro,Kitagawa Yuko

Publisher

Elsevier BV

Subject

Oncology

Reference36 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Cancer,2015

2. The epidemic of oesophageal carcinoma: where are we now?;Thrift;Cancer Epidemiol,2016

3. Global cancer statistics, 2012;Torre;CA Cancer J Clin,2015

4. Comprehensive registry of esophageal cancer in Japan, 2009;Tachimori;Esophagus,2016

5. Effect of alcohol consumption, cigarette smoking and flushing response on esophageal cancer risk: a population-based cohort study (JPHC study);Ishiguro;Cancer Lett,2009

Cited by 322 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic value of tumor‐infiltrating lymphocytes and PD‐L1 expression in esophageal squamous cell carcinoma;Cancer Medicine;2024-09

2. Investigating the impact of the inflammatory immune microenvironment and steroids or COX-2 inhibitors usage on immunotherapy in advanced esophageal squamous cell carcinoma (ESCC): a propensity score matched analysis;Clinical and Translational Oncology;2024-08-23

3. Immune Checkpoint Inhibitors in Esophageal Carcinoma;Surgical Oncology Clinics of North America;2024-07

4. A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12);OncoImmunology;2024-06-24

5. Advancements in immunotherapy for advanced esophageal squamous cell carcinoma: a comprehensive review of current strategies and future directions;Expert Review of Clinical Immunology;2024-06-17